USD 0.83
(-0.97%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 8.53 Million USD | -41.76% |
2022 | 14.64 Million USD | -19.74% |
2021 | 18.25 Million USD | -3.52% |
2020 | 18.91 Million USD | -20.25% |
2019 | 23.71 Million USD | -8.75% |
2018 | 25.99 Million USD | 24.91% |
2017 | 20.8 Million USD | -13.74% |
2016 | 24.12 Million USD | -15.78% |
2015 | 28.64 Million USD | -15.43% |
2014 | 33.86 Million USD | 139.41% |
2013 | 14.14 Million USD | 5.6% |
2012 | 13.39 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 5.82 Million USD | -31.71% |
2024 Q2 | 5.95 Million USD | 2.15% |
2023 FY | 8.53 Million USD | -41.76% |
2023 Q3 | 6.58 Million USD | -8.66% |
2023 Q2 | 7.2 Million USD | -53.38% |
2023 Q1 | 15.45 Million USD | 5.54% |
2023 Q4 | 8.53 Million USD | 29.59% |
2022 Q3 | 19.18 Million USD | 4.89% |
2022 Q1 | 18.07 Million USD | -0.96% |
2022 Q4 | 14.64 Million USD | -23.63% |
2022 FY | 14.64 Million USD | -19.74% |
2022 Q2 | 18.28 Million USD | 1.16% |
2021 Q1 | 18.08 Million USD | -4.42% |
2021 FY | 18.25 Million USD | -3.52% |
2021 Q2 | 18.95 Million USD | 4.84% |
2021 Q3 | 20.12 Million USD | 6.18% |
2021 Q4 | 18.25 Million USD | -9.32% |
2020 Q2 | 22.51 Million USD | -0.94% |
2020 Q4 | 18.91 Million USD | 1.61% |
2020 FY | 18.91 Million USD | -20.25% |
2020 Q1 | 22.72 Million USD | -4.18% |
2020 Q3 | 18.61 Million USD | -17.32% |
2019 Q2 | 24.75 Million USD | 3.15% |
2019 FY | 23.71 Million USD | -8.75% |
2019 Q4 | 23.71 Million USD | -5.52% |
2019 Q3 | 25.1 Million USD | 1.41% |
2019 Q1 | 23.99 Million USD | -7.68% |
2018 Q2 | 30.36 Million USD | 438.93% |
2018 Q1 | 5.63 Million USD | -9.13% |
2018 FY | 25.99 Million USD | 24.91% |
2018 Q4 | 25.99 Million USD | 0.83% |
2018 Q3 | 25.78 Million USD | -15.09% |
2017 Q2 | 6.95 Million USD | -21.33% |
2017 FY | 20.8 Million USD | -13.74% |
2017 Q4 | 6.19 Million USD | 3.38% |
2017 Q3 | 5.99 Million USD | -13.79% |
2017 Q1 | 8.84 Million USD | 4.98% |
2016 Q3 | 9.76 Million USD | -6.17% |
2016 Q2 | 10.4 Million USD | -62.86% |
2016 Q1 | 28.02 Million USD | -2.17% |
2016 FY | 24.12 Million USD | -15.78% |
2016 Q4 | 8.42 Million USD | -13.74% |
2015 Q4 | 28.64 Million USD | 0.23% |
2015 Q3 | 28.57 Million USD | -8.73% |
2015 Q2 | 31.3 Million USD | -5.35% |
2015 Q1 | 33.08 Million USD | -2.33% |
2015 FY | 28.64 Million USD | -15.43% |
2014 Q4 | 33.86 Million USD | -2.27% |
2014 Q3 | 34.65 Million USD | 1.27% |
2014 Q2 | 34.21 Million USD | 141.82% |
2014 Q1 | 14.15 Million USD | 0.03% |
2014 FY | 33.86 Million USD | 139.41% |
2013 Q1 | 15.65 Million USD | 16.87% |
2013 FY | 14.14 Million USD | 5.6% |
2013 Q3 | 18.29 Million USD | 1.47% |
2013 Q2 | 18.02 Million USD | 15.12% |
2013 Q4 | 14.14 Million USD | -22.65% |
2012 Q4 | 13.39 Million USD | 0.0% |
2012 FY | 13.39 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Editas Medicine, Inc. | 150.05 Million USD | 94.315% |
Dynavax Technologies Corporation | 375.02 Million USD | 97.725% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 98.25% |
Perrigo Company plc | 6.04 Billion USD | 99.859% |
Illumina, Inc. | 4.36 Billion USD | 99.805% |
Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.984% |
Iovance Biotherapeutics, Inc. | 195.73 Million USD | 95.642% |
Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.988% |
IQVIA Holdings Inc. | 20.56 Billion USD | 99.959% |
Heron Therapeutics, Inc. | 256.47 Million USD | 96.674% |
Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.88% |
Unity Biotechnology, Inc. | 37.29 Million USD | 77.125% |
Waters Corporation | 3.47 Billion USD | 99.755% |
Biogen Inc. | 12.04 Billion USD | 99.929% |
Sangamo Therapeutics, Inc. | 82.43 Million USD | 89.652% |
Evolus, Inc. | 209.68 Million USD | 95.932% |
Adicet Bio, Inc. | 37.12 Million USD | 77.019% |
Cara Therapeutics, Inc. | 68.75 Million USD | 87.594% |
bluebird bio, Inc. | 424.62 Million USD | 97.991% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 98.709% |
FibroGen, Inc. | 585.72 Million USD | 98.544% |
Agilent Technologies, Inc. | 4.91 Billion USD | 99.827% |
Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | 75.75% |
Homology Medicines, Inc. | 118.53 Million USD | 92.803% |
Geron Corporation | 146.12 Million USD | 94.162% |
Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.789% |
Amicus Therapeutics, Inc. | 617.7 Million USD | 98.619% |
Myriad Genetics, Inc. | 312.9 Million USD | 97.274% |
Viking Therapeutics, Inc. | 20.07 Million USD | 57.499% |
Intellia Therapeutics, Inc. | 250.8 Million USD | 96.599% |
Zoetis Inc. | 9.29 Billion USD | 99.908% |
Abeona Therapeutics Inc. | 49.17 Million USD | 82.653% |
Mettler-Toledo International Inc. | 3.5 Billion USD | 99.757% |
BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 99.549% |
Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.834% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | 82.392% |
Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 99.672% |
Atara Biotherapeutics, Inc. | 264.73 Million USD | 96.778% |
Verastem, Inc. | 71.18 Million USD | 88.017% |
Nektar Therapeutics | 267.04 Million USD | 96.806% |
Axsome Therapeutics, Inc. | 397.25 Million USD | 97.853% |
Aclaris Therapeutics, Inc. | 40.22 Million USD | 78.794% |
Sarepta Therapeutics, Inc. | 2.4 Billion USD | 99.645% |
OPKO Health, Inc. | 622.47 Million USD | 98.63% |
Exelixis, Inc. | 678.44 Million USD | 98.743% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.163% |
Corcept Therapeutics Incorporated | 114.81 Million USD | 92.57% |
Anavex Life Sciences Corp. | 12.53 Million USD | 31.942% |
uniQure N.V. | 624.01 Million USD | 98.633% |
Blueprint Medicines Corporation | 918.64 Million USD | 99.071% |
Insmed Incorporated | 1.66 Billion USD | 99.487% |
Halozyme Therapeutics, Inc. | 1.64 Billion USD | 99.483% |
Agios Pharmaceuticals, Inc. | 126.09 Million USD | 93.235% |
TG Therapeutics, Inc. | 169.08 Million USD | 94.955% |
Incyte Corporation | 1.59 Billion USD | 99.464% |
Emergent BioSolutions Inc. | 1.18 Billion USD | 99.28% |